The 31-valent pneumococcal conjugate vaccine met all co-primary endpoints vs Prevnar 20 and Capvaxive, with superiority on 3 unique serotypes + cross-reactive 20B. Could add 13–36% IPD and 19–31% pneumonia coverage over today's adult PCVs. BLA planned H1 2028.
Pneumococcal trackerAll four FDA-approved XFG formulations now shipping: Comirnaty XFG (Pfizer-BioNTech), Spikevax XFG & mNEXSPIKE XFG (Moderna), and Nuvaxovid XFG (Novavax/Sanofi). Narrow indication retained: adults ≥65 or 6mo–64 with high-risk condition.
COVID-19 trackerModerna's mRNA-1010, FDA-approved 5 Aug 2026, reaches US retailers for the 2026–27 respiratory season. Full approval for adults 50–64; accelerated approval for ≥65 (postmarketing high-dose comparator trial required).
Influenza trackerThe Aug 2025 cancellation of 22 mRNA investments (~$500M) is now visibly influencing which next-generation respiratory, HIV, and pandemic-preparedness candidates advance. Academic groups and CEPI are quietly picking up discontinued work.
Related trackersCollection last refreshed October 2026. The Clinical Corner vaccine database covers 60+ vaccines across preventive infectious disease, therapeutic (cancer, Alzheimer's, Parkinson's, MS, T1D), and outbreak-response tracks. Notable 2025–2026 highlights across the collection: Vimkunya (chikungunya, FDA Feb 2025); Capvaxive (PCV21, FDA June 2024, ACIP age lowered to 50+); mFlusiva mRNA seasonal flu (FDA Aug 5, 2026); XFG-adapted COVID vaccines (FDA Aug 27–28, 2026); VAX-31 31-valent PCV Phase 3 win (Oct 5, 2026); M72/AS01E TB Phase 3 enrolled ~20,080; Moderna CMV mRNA-1647 Phase 3 failed and discontinued; Pfizer/Valneva Lyme VLA15 Phase 3 VALOR 73% efficacy; Bundibugyo Ebola PHEIC (May 17, 2026); US measles cases exceeding 2,300 (highest since 1991); Rwanda + Ethiopia Marburg outbreaks with Sabin cAd3-Marburg deployed.
Comprehensive tracking of 53 major vaccine programs from preclinical to FDA approval.